618 related articles for article (PubMed ID: 9343181)
1. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
3. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
[TBL] [Abstract][Full Text] [Related]
4. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
5. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
6. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.
Callebaut C; Blanco J; Benkirane N; Krust B; Jacotot E; Guichard G; Seddiki N; Svab J; Dam E; Muller S; Briand JP; Hovanessian AG
J Biol Chem; 1998 Aug; 273(34):21988-97. PubMed ID: 9705340
[TBL] [Abstract][Full Text] [Related]
7. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.
Thali M; Furman C; Wahren B; Posner M; Ho DD; Robinson J; Sodroski J
J Acquir Immune Defic Syndr (1988); 1992; 5(6):591-9. PubMed ID: 1588493
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
Burkly L; Mulrey N; Blumenthal R; Dimitrov DS
J Virol; 1995 Jul; 69(7):4267-73. PubMed ID: 7769687
[TBL] [Abstract][Full Text] [Related]
10. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
11. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
Trkola A; Dragic T; Arthos J; Binley JM; Olson WC; Allaway GP; Cheng-Mayer C; Robinson J; Maddon PJ; Moore JP
Nature; 1996 Nov; 384(6605):184-7. PubMed ID: 8906796
[TBL] [Abstract][Full Text] [Related]
12. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
13. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
Moore JP; Ho DD
J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
16. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
McKeating JA; Cordell J; Dean CJ; Balfe P
Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
[TBL] [Abstract][Full Text] [Related]
18. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
19. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
20. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
